Studies of stem cell biology and transplant approaches presented at the 54th Annual Meeting of the American Society of Haematology (ASH) illustrate how the use of advanced modelling… read more.
New research, presented at the 54th Annual Meeting of the American Society of Haematology (ASH), has identified important associations between Plasmodium falciparum (Pf) malaria and endemic Burkitt Lymphoma (eBL) that… read more.
by Sung Choi, M.D., University of Michigan Comprehensive Cancer Center (pictured) First study in humans shows promise for preventing graft-versus-host disease following bone marrow transplant.
The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic… read more.
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3… read more.
Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome,
Therapy may be new option for hard-to-treat blood cancer.
Proof-of-concept animal study selected as one of the best presentations at 54th American Society of Hematology Annual Meeting and Exposition.
Data demonstrate superior patient outcomes with B-R in first-line treatment of iNHL and MCL, compared with current standard of care.
by Marybeth Burke – Median progression-free survival (PFS) was significantly greater in the trametinib group, 4.8 months, vs the chemotherapy group, 1.4 months, according to a study presented
by Marybeth Burke – Afatinib, an irreversible ErbB-family blocker, delays progression of advanced lung cancer in patients with epidermal growth factor receptor (EGFR) mutations compared with standard chemotherapy,
25 Feb 2012 – EAU Paris – Men often finds it difficult to talk with primary health specialists and this is certainly true in the case of BPH.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
